BioSpace News Archive

Curasight A/S announces that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Anocca AB announced the appointment of Martin Welschof to its Board of Directors.

Immuron Limited is pleased to announce record sales of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract.

Kraig Biocraft Laboratories, Inc., announces it has now taken possession of its new recombinant spider silk production center in Lam Dong Province, Vietnam.

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the first patient dosed in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, “beta-enhanced not-alpha” interleukin-2 (IL-2) super-agonist, with KEYTRUDA® (pembrolizumab).

LianBio announced that the Company’s Board of Directors had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares, each representing the right to receive one ordinary share, from the Nasdaq Global Market and deregistration under Section 12 of the Securities Exchange Act of 1934 and workforce reductions.

Scinai Immunotherapeutics Ltd. announced the appointment of Liat Halpert as Head of Business Development and Sales.

Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, hosted members of Congress focused on strengthening the U.S. bioeconomy in service of national and economic security yesterday.

Nicoya®, a pioneering life science instrument company specializing in innovative biosensor technology, is pleased to announce the appointment of Medispec as its exclusive distributor in India.

Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec’s Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company’s Radixact® radiation therapy delivery system.